Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease — a real-world outcomes analysis

Sameem Abedin, Nahid Rashid, Mark Schroeder, Rizwan Romee, Mary Nauffal, Muhamad Alhaj Moustafa, Mohamed A. Kharfan-Dabaja, Jeanne Palmer, William Hogan, Mehrdad Hefazi, Samantha Larson, Shernan Holtan, Zachariah DeFilipp, Reena Jayani, Bhagirathbhai Dholaria, Joseph Pidala, Farhad Khimani, Michael R. Grunwald, Candace Butler, Mehdi Hamadani

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Ruxolitinib for steroid-refractory acute graft-versus-host disease (SR-aGVHD) results in resistance or intolerance in 1/5 of patients. Outcomes of such patients are undefined. We identified these patients in a multicentre review and reported outcomes. Ruxolitinib-resistant aGVHD was identified in 48/307 patients. Among patients receiving additional therapy, the overall response rate to next therapy was 36%. Median survival was 21 days. Ruxolitinib intolerance led to treatment discontinuation in 16/307 patients. Ten intolerant patients received additional therapy with 50% experiencing continued improvement of aGVHD. Median survival was 50 days in these patients. These data serve as a baseline for future SR-aGVHD studies.

Original languageEnglish
Pages (from-to)429-432
Number of pages4
JournalBritish Journal of Haematology
Volume195
Issue number3
DOIs
StatePublished - Nov 2021

Keywords

  • graft-versus-host disease
  • stem cell transplantation
  • transplant

Fingerprint

Dive into the research topics of 'Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease — a real-world outcomes analysis'. Together they form a unique fingerprint.

Cite this